Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2487人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866597, encodeId=b1b0186659e25, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：3期结肠癌术后标准辅助治疗时间可缩短至3个月！, objectType=article, longId=726370, objectId=9aace26370c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aace26370c2, replyNumber=0, likeNumber=93, createdTime=2022-05-10, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aace26370c2, moduleTitle=J Clin Oncol：3期结肠癌术后标准辅助治疗时间可缩短至3个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aace26370c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866444, encodeId=2d1c186644434, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：Merkel细胞癌（MCC）的临床病理特点、治疗策略及影响预后的因素, objectType=article, longId=292943, objectId=93c2292943e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93c2292943e7, replyNumber=0, likeNumber=73, createdTime=2022-11-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93c2292943e7, moduleTitle=Front Oncol：Merkel细胞癌（MCC）的临床病理特点、治疗策略及影响预后的因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93c2292943e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866584, encodeId=664c186658432, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效, objectType=article, longId=723407, objectId=bf1be2340744, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1be2340744, replyNumber=0, likeNumber=83, createdTime=2022-04-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1be2340744, moduleTitle=Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1be2340744)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866461, encodeId=7cef1866461e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：徐兵河院士团队发现HER2-乳腺癌中HER2低表达可能是预后良好指标, objectType=article, longId=294156, objectId=e468294156ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e468294156ec, replyNumber=0, likeNumber=60, createdTime=2022-09-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e468294156ec, moduleTitle=Front Oncol：徐兵河院士团队发现HER2-乳腺癌中HER2低表达可能是预后良好指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e468294156ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866665, encodeId=5d2d1866665f6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncology：关于肾移植受者免疫检查点抑制剂治疗的影响——一项多中心、单臂、1期研究, objectType=article, longId=732651, objectId=fb71e32651ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb71e32651ee, replyNumber=0, likeNumber=94, createdTime=2023-03-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb71e32651ee, moduleTitle=Lancet Oncology：关于肾移植受者免疫检查点抑制剂治疗的影响——一项多中心、单臂、1期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb71e32651ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866567, encodeId=09b7186656eca, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, objectType=article, longId=301442, objectId=1e71301442a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e71301442a7, replyNumber=0, likeNumber=91, createdTime=2023-02-26, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e71301442a7, moduleTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e71301442a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866379, encodeId=0a4718663e977, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后, objectType=article, longId=221235, objectId=6ad622123581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad622123581, replyNumber=0, likeNumber=90, createdTime=2022-06-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad622123581, moduleTitle=Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad622123581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866248, encodeId=f850186624865, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性, objectType=article, longId=217605, objectId=134f21e60540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134f21e60540, replyNumber=0, likeNumber=78, createdTime=2022-09-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134f21e60540, moduleTitle=J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134f21e60540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866542, encodeId=58171866542f9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, objectType=article, longId=300705, objectId=242e300e0568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242e300e0568, replyNumber=0, likeNumber=78, createdTime=2022-12-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242e300e0568, moduleTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242e300e0568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866466, encodeId=e9b1186646629, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, objectType=article, longId=294620, objectId=03df29462025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03df29462025, replyNumber=0, likeNumber=102, createdTime=2022-12-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03df29462025, moduleTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03df29462025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866286, encodeId=1f7118662863b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：纳武单抗联合低剂量伊匹单抗一线治疗MSI-H/dMMR转移性结直肠癌的疗效, objectType=article, longId=218587, objectId=a0e721858e65, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0e721858e65, replyNumber=0, likeNumber=80, createdTime=2021-12-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0e721858e65, moduleTitle=J Clin Oncol：纳武单抗联合低剂量伊匹单抗一线治疗MSI-H/dMMR转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0e721858e65)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866479, encodeId=267318664e9d4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效, objectType=article, longId=295059, objectId=afe5295059f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe5295059f2, replyNumber=0, likeNumber=80, createdTime=2022-07-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe5295059f2, moduleTitle=Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe5295059f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866434, encodeId=b4ca18664346f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：宫颈癌前病变和浸润性宫颈癌的易感遗传变异！, objectType=article, longId=293018, objectId=94aa293018dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94aa293018dd, replyNumber=0, likeNumber=28, createdTime=2022-08-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94aa293018dd, moduleTitle=Lancet Oncol：宫颈癌前病变和浸润性宫颈癌的易感遗传变异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94aa293018dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866438, encodeId=00c51866438ec, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效, objectType=article, longId=293027, objectId=84b729302ea0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b729302ea0, replyNumber=0, likeNumber=20, createdTime=2022-06-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b729302ea0, moduleTitle=Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b729302ea0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Hematol Oncol：口服阿扎胞苷治疗缓解期AML患者的不良事件, objectType=article, longId=216585, objectId=d493216585e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d493216585e2, replyNumber=0, likeNumber=0, createdTime=2022-05-26, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d493216585e2, moduleTitle=J Hematol Oncol：口服阿扎胞苷治疗缓解期AML患者的不良事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d493216585e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866276, encodeId=5e3d18662e696, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：卡瑞珠单抗联合阿帕替尼有望成为化疗难治性/复发性妊娠滋养细胞肿瘤的挽救治疗方案！, objectType=article, longId=218250, objectId=f5da2182509d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5da2182509d, replyNumber=0, likeNumber=81, createdTime=2022-09-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5da2182509d, moduleTitle=Lancet Oncol：卡瑞珠单抗联合阿帕替尼有望成为化疗难治性/复发性妊娠滋养细胞肿瘤的挽救治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5da2182509d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866345, encodeId=f27318663452c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：大型前瞻性GWAS鉴定预测奥沙利铂介导的周围感觉神经病变(PSN)的单核苷酸多态性(SNPs), objectType=article, longId=220257, objectId=925e22025e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925e22025e7a, replyNumber=0, likeNumber=68, createdTime=2022-03-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925e22025e7a, moduleTitle=Ann Oncol：大型前瞻性GWAS鉴定预测奥沙利铂介导的周围感觉神经病变(PSN)的单核苷酸多态性(SNPs), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925e22025e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866503, encodeId=5c87186650319, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, objectType=article, longId=295593, objectId=ab9629559335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab9629559335, replyNumber=0, likeNumber=70, createdTime=2022-08-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab9629559335, moduleTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab9629559335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866449, encodeId=a7761866449ad, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：结直肠癌患者T4a和T4b期的预后比较, objectType=article, longId=293539, objectId=148b29353912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=148b29353912, replyNumber=0, likeNumber=80, createdTime=2022-09-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=148b29353912, moduleTitle=Front Oncol：结直肠癌患者T4a和T4b期的预后比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=148b29353912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866365, encodeId=b91e186636524, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：神经激肽-1受体拮抗剂fosnetupitant (FosNTP)对比fosaprepitant (FosAPR)预防高致吐性化疗引起的恶心和呕吐的有效性和安全性, objectType=article, longId=220833, objectId=ff7e22083386, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff7e22083386, replyNumber=0, likeNumber=62, createdTime=2022-03-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff7e22083386, moduleTitle=J Clin Oncol：神经激肽-1受体拮抗剂fosnetupitant (FosNTP)对比fosaprepitant (FosAPR)预防高致吐性化疗引起的恶心和呕吐的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff7e22083386)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：3期结肠癌术后标准辅助治疗时间可缩短至3个月！

2022-05-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：Merkel细胞癌（MCC）的临床病理特点、治疗策略及影响预后的因素

2022-11-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效

2022-04-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：徐兵河院士团队发现HER2-乳腺癌中HER2低表达可能是预后良好指标

2022-09-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncology：关于肾移植受者免疫检查点抑制剂治疗的影响——一项多中心、单臂、1期研究

2023-03-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险

2023-02-26

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后

2022-06-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性

2022-09-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS

2022-12-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后

2022-12-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：纳武单抗联合低剂量伊匹单抗一线治疗MSI-H/dMMR转移性结直肠癌的疗效

2021-12-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：复发或转移性头颈部鳞癌(R/M HNSCC)患者使用免疫检查点抑制剂治疗(ICB)的疗效

2022-07-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：宫颈癌前病变和浸润性宫颈癌的易感遗传变异！

2022-08-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：3期| 尼拉帕利维持治疗铂敏感性复发性卵巢癌中国患者的疗效

2022-06-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Hematol Oncol：口服阿扎胞苷治疗缓解期AML患者的不良事件

2022-05-26

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：卡瑞珠单抗联合阿帕替尼有望成为化疗难治性/复发性妊娠滋养细胞肿瘤的挽救治疗方案！

2022-09-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：大型前瞻性GWAS鉴定预测奥沙利铂介导的周围感觉神经病变(PSN)的单核苷酸多态性(SNPs)

2022-03-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期

2022-08-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：结直肠癌患者T4a和T4b期的预后比较

2022-09-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：神经激肽-1受体拮抗剂fosnetupitant (FosNTP)对比fosaprepitant (FosAPR)预防高致吐性化疗引起的恶心和呕吐的有效性和安全性

2022-03-28

科室
- - 订阅+
  - 更多科室
工具
服务